Shroom Investor 🍄 – Page 3 – Psychedelics Stocks Investing News & Watch List

VANCOUVER, BC, Aug. 9, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Nikhil Handa, CFO, will participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023, at... Read More...

61 views8 min read

Red Light Holland Announces Happy Caps Mushroom Farm Signs Distribution Deal with Longo Brothers Fruit Markets Inc. – Longo’s

Happy Caps Mushroom Home Grow Kits will soon be available in over 135 retail stores across Canada, including Longo's 31 locations in southern Ontario.Distribution agreement to commence September 15, 2023.Happy Caps' Lion's Mane, Shiitake, and Oyster mushroom kits sell for $25-$30 (MSRP) via www.HappyCaps.ca, Amazon (both USA and Canada), ... Read More...

277 views8 min read

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders-- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study-- Pro... Read More...

113 views6 min read

Cybin Announces Closing of Overnight Marketed Public Offering of Units

Cybin

TORONTO, August 04, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has closed its previously announced... Read More...

1071 views7 min read

Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder

Cybin

- To date, CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg -- Phase 2 topline efficacy data expected in Q3/Q4 2023 -TORONTO, August 02, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutica... Read More...

1000 views8 min read

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

Psyence Group

VANCOUVER, British Columbia, Aug. 02, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) toda... Read More...

1279 views7 min read

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units

Cybin

TORONTO, August 01, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricing of its previously announced overnight ... Read More...

381 views8 min read

Red Light Holland’s Psilocybin Microdosing Homogenized Capsules Receive Finalized Certificate of Analysis by CCREST Laboratories

The natural psilocybin microdosing capsules, developed from psilocybin truffles grown in Red Light Holland's farm in The Netherlands, have received the results of the successful final tests required for a Certificate of Analysis.Finalized Certificate of Analysis indicates Red Light Holland's lab tested Truffles meets initial requirement f... Read More...

970 views8 min read

Cybin Announces Overnight Marketed Public Offering of Units

Cybin

TORONTO, July 31, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has launched an overnight marketed pu... Read More...

Financials1102 views6 min read

Red Light Holland Reports 2023 Audited Year End Results

Cash balance of $18.5 million as at March 31, 2023Revenue of $3.95 million (vs 2022: $2.3 million, an increase of 69.8%)Gross profit of $1.7 million (vs 2022: $0.6 million, an increase of 176.3%)Property and equipment value of $4.8 millionTotal assets of $30.1 millionToronto, Ontario--(Newsfile Corp. - July 31, 2023) - Red Light Holland C... Read More...

730 views2 min read

Optimi Health Announces Receipt of Purported Termination Notice

Optimi Health

VANCOUVER, British Columbia, July 27, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on developing mushroom-based therapeutics. For further... Read More...

Joint Venture882 views7 min read

Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder

Cybin

-Collaboration with Worldwide Clinical Trials provides Cybin with access to a contract research organization with substantial experience supporting multinational psychedelic clinical trials -- Cybin expects to report Phase 2 topline efficacy data for CYB003 in major depressive disorder in Q3/Q4 2023 -TORONTO, July 26, 2023--(BUSINESS WIRE... Read More...

1111 views6 min read

Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder

Cybin

- Cohort 5 completed with no safety or tolerability issues, Final cohort 6 is recruiting with dosing expected to commence shortly - - Phase 2 efficacy data for CYB003 in major depressive disorder expected in Q3/Q4 2023 - - U.S. Food and Drug Administration ("FDA") submission of CYB003 Phase 1/2a data for pivotal studies expected following... Read More...

1006 views6 min read

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders-- BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending do... Read More...

140 views8 min read

Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin

TORONTO, July 20, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leader in non-invasive neuroimaging, on their pub... Read More...

711 views5 min read

PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

PharmaTher Holdings

TORONTO, July 18, 2023 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce that it has successfully completed a research study evaluating PharmaPatch™, a proprietary microneedle patch, in delivering N,N-dimethyltryptamine (“DM... Read More...

Financials858 views16 min read

Numinus Wellness Inc. Reports Q3 2023 Results

Q3 2023 revenues grew 713.3% year-over-year to $6.0 million Q3 2023 revenues grew 12.6% from previous quarter Gross profit of $2.1 million, increased 1051.6% year-over-year Staff reductions and operational realignment resulted in $0.6 million of one-time expenses during the quarter Cash position of $13.0 million as at May 31, 2023 Activi... Read More...

246 views8 min read

Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT

Cybin

- EMBARK for Clinical Trials ("EMBARKCT") being developed as a scalable model of psychedelic facilitation training to support future pivotal studies -- American Medical Association ("AMA")’s new CPT codes will support potential reimbursement of in-person monitoring and support provided during psychedelic treatment-TORONTO, July 12, 2023--... Read More...

240 views3 min read

Bright Minds Announces Effective Date of Share Consolidation

VANCOUVER, British Columbia, July 11, 2023 -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the ... Read More...

1206 views6 min read

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics

TORONTO, July 06, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced results of the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734... Read More...

79 views3 min read

Aion Therapeutic Announces Proposed Non-Brokered Private Placement Offering of Units

Aion Therapeutic

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE U.S./TORONTO, July 4, 2023 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it plans to undertake a non-brokered private placement of up to 50,000,000 units ("Units") to raise gross proceeds of up to $500,000.00... Read More...

327 views6 min read

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer

Cybin

This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplement dated August 8, 2022 and prospectus supplement dated May 30, 2023 to its short form base shelf prospectus dated July 5, 2021TORONTO, June 29, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company... Read More...

CalendarFinancials877 views3 min read

Numinus to Host Q3 2023 Results Conference Call on July 17, 2023

VANCOUVER, BC, June 29, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended May 31, 2023, after market close on Monday, July 17, 2023. Interested pa... Read More...

915 views8 min read

Red Light Holland Announces Shares Buyback Under Normal Course Issuer Bid

Toronto, Ontario--(Newsfile Corp. - June 28, 2023) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truff... Read More...

Financials115 views10 min read

Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights

Cybin

- Initiated First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial -- Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB0041,2 -- U.S. Food and Drug Administration ("FDA") submission of CYB003 Phase 1/2a data for end of phase 2 meeting expected in Q4 20231,2 -This... Read More...

124 views4 min read

Lobe Sciences Initiates Phase 1 Clinical Trial of L-130

Lobe Sciences

First-in-Man trial for Lobe’s proprietary stabilized psilocin analogueAll subjects dosed with no significant adverse events to dateVANCOUVER, British Columbia, June 27, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare dis... Read More...

46 views4 min read

Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers

Silo Pharma

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / June 23, 2023 / This month, Silo Pharma (NASDAQ:SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. The development-stage biopharma company has a portfolio of therapies in its pipeline that merge trad... Read More...

537 views3 min read

Bright Minds Announces Proposed Share Consolidation

VANCOUVER, British Columbia, June 22, 2023 -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it intends to consolidate its common shares (the “C... Read More...

27 views6 min read

Red Light Holland Begins Stability Testing For Its Psilocybin Microdosing Capsules Developed and Tested By Partner CCrest Laboratories Aimed For Distribution With NUBU Pharmaceuticals In Australasia

Stability tests for the dehydrated homogenized psilocybin truffles grown in Red Light Holland farms in the Netherlands, required for transforming the natural truffles into medicinal microdosing capsules has started, following encapsulation.Toronto, Ontario--(Newsfile Corp. - June 19, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) ... Read More...

372 views11 min read

Red Light Holland Announces Happy Caps Mushroom Home Grow Kits Are Now Available in 36 Canadian Tire Stores, Exceeding 110 Retail Locations in Canada

Happy Caps Home Grow Kits are now available in 36 Canadian Tire stores across Canada, increasing points of sales by 64% since February 2023, with a plan to add additional locations in the near term futureWith the addition of the new Canadian Tire Stores, Happy Caps Home Grow Mushroom Kits are now available in over 110 retail stores in Can... Read More...

59 views4 min read

Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS

Optimi Health

VANCOUVER, British Columbia, June 15, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as GMP-grade 3,4-Me... Read More...

113 views4 min read

Numinus Appoints New Chief Financial Officer